Ruth Daniels, Wim Van der Elst, Chi K So, Liesbeth Voeten, Philip Breugelmans, Marijke W A Molenaar-de Backer, Stephen Poole, Mehul Patel
{"title":"适合目的测试和独立的GMP验证单核细胞活化试验。","authors":"Ruth Daniels, Wim Van der Elst, Chi K So, Liesbeth Voeten, Philip Breugelmans, Marijke W A Molenaar-de Backer, Stephen Poole, Mehul Patel","doi":"10.1016/j.crtox.2024.100206","DOIUrl":null,"url":null,"abstract":"<p><p>The present study describes the \"fit for purpose\" testing and the independent product-specific GMP validation of the monocyte activation test (MAT) to detect pyrogenic and pro-inflammatory contaminants, MAT Method A, Quantitative Test (European Pharmacopoeia, Ph. Eur. chapter 2.6.30, 2017). A fit for purpose study was carried out to ensure that the chosen MAT set-up (cryopreserved PBMC, IL-6 detection) can reliably discriminate between batches of product containing pyrogenic contaminants below the contaminants limit concentration, CLC, from batches containing pyrogenic contaminants above the CLC. Such testing is carried out once, before the chosen MAT set-up is used for subsequent product testing to show that the incidence of false positives (pyrogen-negative (<CLC) batches testing as pyrogen-positive (>CLC) batches) and - especially - false negatives (pyrogen-positive (>CLC) testing as pyrogen-negative (<CLC)) is low. This study also afforded the opportunity to collect an independent body of validation data for comparison with that obtained previously (Daniels et al., 2022) to evaluate the robustness of MAT Method A and its fitness to replace the rabbit pyrogen test (RPT) where this has not already happened.</p>","PeriodicalId":11236,"journal":{"name":"Current Research in Toxicology","volume":"8 ","pages":"100206"},"PeriodicalIF":2.9000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721511/pdf/","citationCount":"0","resultStr":"{\"title\":\"Fit for purpose testing and independent GMP validation of the monocyte activation test.\",\"authors\":\"Ruth Daniels, Wim Van der Elst, Chi K So, Liesbeth Voeten, Philip Breugelmans, Marijke W A Molenaar-de Backer, Stephen Poole, Mehul Patel\",\"doi\":\"10.1016/j.crtox.2024.100206\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The present study describes the \\\"fit for purpose\\\" testing and the independent product-specific GMP validation of the monocyte activation test (MAT) to detect pyrogenic and pro-inflammatory contaminants, MAT Method A, Quantitative Test (European Pharmacopoeia, Ph. Eur. chapter 2.6.30, 2017). A fit for purpose study was carried out to ensure that the chosen MAT set-up (cryopreserved PBMC, IL-6 detection) can reliably discriminate between batches of product containing pyrogenic contaminants below the contaminants limit concentration, CLC, from batches containing pyrogenic contaminants above the CLC. Such testing is carried out once, before the chosen MAT set-up is used for subsequent product testing to show that the incidence of false positives (pyrogen-negative (<CLC) batches testing as pyrogen-positive (>CLC) batches) and - especially - false negatives (pyrogen-positive (>CLC) testing as pyrogen-negative (<CLC)) is low. This study also afforded the opportunity to collect an independent body of validation data for comparison with that obtained previously (Daniels et al., 2022) to evaluate the robustness of MAT Method A and its fitness to replace the rabbit pyrogen test (RPT) where this has not already happened.</p>\",\"PeriodicalId\":11236,\"journal\":{\"name\":\"Current Research in Toxicology\",\"volume\":\"8 \",\"pages\":\"100206\"},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-12-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721511/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Research in Toxicology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.crtox.2024.100206\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"TOXICOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Toxicology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.crtox.2024.100206","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"TOXICOLOGY","Score":null,"Total":0}
Fit for purpose testing and independent GMP validation of the monocyte activation test.
The present study describes the "fit for purpose" testing and the independent product-specific GMP validation of the monocyte activation test (MAT) to detect pyrogenic and pro-inflammatory contaminants, MAT Method A, Quantitative Test (European Pharmacopoeia, Ph. Eur. chapter 2.6.30, 2017). A fit for purpose study was carried out to ensure that the chosen MAT set-up (cryopreserved PBMC, IL-6 detection) can reliably discriminate between batches of product containing pyrogenic contaminants below the contaminants limit concentration, CLC, from batches containing pyrogenic contaminants above the CLC. Such testing is carried out once, before the chosen MAT set-up is used for subsequent product testing to show that the incidence of false positives (pyrogen-negative (CLC) batches) and - especially - false negatives (pyrogen-positive (>CLC) testing as pyrogen-negative (
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
